Apoptosis as a tool for therapeutic agents in haematological diseases

Bibliography

• MAJNO G, JORIS I: Apoptosis, oncosis, and necrosis: an overview of cell death. Am. Pathol (1995) 146:3–15.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ LM, OSBORNE BA: Programmed cell death, apoptosis and killer genes. Immunol Today (1993) 14:582–590.
   PubMedGoogle Scholar
• THOMPSON CB: Apoptosis in the pathogenesis and treatment of disease. Science (1995) 267:1456–1462.
   PubMed Web of Science ®Google Scholar
• SAVILL J: Apoptosis in disease. Eui: Clin. Invest. (1994) 24:715–723.
   PubMed Web of Science ®Google Scholar
• REVILLARD JP, ADORINI L, GOLDMAN M, KABELITZ, D, WALDMANN H: Apoptosis: potential for disease therapies. Immunol Today (1998) 19:291–293.
   PubMedGoogle Scholar
• RUDIN CM, THOMPSON CB: Apoptosis and disease: regulation and clinical relevance of programmed cell death. Ann. Rev Med. (1997) 48:267–281.
   PubMed Web of Science ®Google Scholar
• VARGHESE J, KHANDRE NS, SARIN A: Caspase-3 activation is an early event and initiates apoptotic damage in a human leukemia cell line. Apoptosis (2003) 8:363–370.
   PubMed Web of Science ®Google Scholar
• ALENZI FQ, WARRENS AN: Cellular and molecular themes in apoptosis. Wien. KIM. Wochenschr. (2003) 115:563–574.
   PubMed Web of Science ®Google Scholar
• DEBATIN KM: Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother: (2004) (Epub ahead of print) (In Press).
   Google Scholar
• LOTEM J, SACHS L: Coupling of growth and differentiation in normal myeloid precursors and the breakdown of this coupling in leukemia. hat. Cancer (1983) 32:127–134.
   Web of Science ®Google Scholar
• LOTEM J, SACHS L: Induction of dependence on hematopoietic proteins for viability and receptor upregulation in differentiating myeloid leukemic cells. Blood (1989) 74:579–585.
   PubMed Web of Science ®Google Scholar
• LOTEM J, SACHS L: In vivo control of differentiation of myeloid leukemic cells by recombinant granulocyte-macrophage colony-stimulating factor and interleukin 3. Blood(1988) 71:375–382.
   PubMed Web of Science ®Google Scholar
• LOTEM J, SACHS L: In vivoinhibition ofthe development of myeloid leukemia by injection of macrophage- and granulocyte-inducing protein. Int. J. Cancer (1981) 28:375–386.
   PubMed Web of Science ®Google Scholar
• LOTEM J, SACHS L: Control of in vivo differentiation of myeloid leukemic cells. IV. Inhibition of leukemia development by myeloid differentiation-inducing protein. Int.j Cancer (1984) 33:147–154.
   Google Scholar
• DEGOS L: Differentiation therapy and leukemia. Leukemia (1993) 7:766–772.
   PubMed Web of Science ®Google Scholar
• FORRAZ N, PETTENGELL R, DEGLESNE PA, MCGUCKIN CP: AC133+ umbilical cord blood progenitors demonstrate rapid self-renewal and low apoptosis. Br. Haematol (2002) 119:516–524.
   PubMed Web of Science ®Google Scholar
• ISMAIL MM, TOOZE JA, FLYNN JA et al.: Differential apoptosis and Fas expression on GPI-negative and GPI-positive stem cells: a mechanism for the evolution of paroxysmal nocturnal haemoglobinuria. Br. Haematol (2003) 123:545–551.
   PubMed Web of Science ®Google Scholar
• YOUNG HE, BLACK AC JR: Adult stem cells. Anat. Rec. (2004) 276A:75–102.
   Google Scholar
• ZHENG X, BEISSERT T, KUKOC-ZIVOJNOV N et al: fgammal-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood (2004) (Epub ahead of print) (In Press).
   Google Scholar
• GORDON MY, BLACKETT NM: Reconstruction of the hematopoietic system after stem cell transplantation. Cell Transplant. (1998) 7:339–344.
   PubMed Web of Science ®Google Scholar
• GORDON MY, BLACKETT NM: Routes to repopulation-a unification of the stochastic model and separation of stem-cell subpopulations. Leukemia (1994) 8:1068–1072.
   PubMed Web of Science ®Google Scholar
• KOURY MJ: Programmed cell death (apoptosis) in hematopoiesis. Exp. Hematol (1992) 20:391–394.
   PubMed Web of Science ®Google Scholar
• TESTA N: Erythroid progenitor cells. Theirrelevance for the study of haematological disease. Clin. Hematol (1979) 8:311–333.
   Google Scholar
• WILLIAMS GT, SMITH CA, SPOONCER E, DEXTER TM, TAYLOR DR: Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature (1990) 343:76–79.
   PubMed Web of Science ®Google Scholar
• DE MARIA R, TESTA U, LUCHETTI L et al.: Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood (1999) 93:796–803.
   PubMed Web of Science ®Google Scholar
• COSMAN D: A family of ligands for the TNF receptor superfamily. Stem Cells (1994) 12:440–455.
   PubMed Web of Science ®Google Scholar
• THEOFILOPOULOS AN, KONO DH: The genes of systemic autoimmunity. Proc. Assoc. Am. Phys. (1999) 111:228–240.
   PubMedGoogle Scholar
• SCHNEIDER E, MOREAU G, ARNOULD A et al.: Increased fetal and extramedullary hematopoiesis in Fas-deficient C57BL/6-1pr/lpr mice. Blood (1999) 94:2613–2621.
   PubMed Web of Science ®Google Scholar
• ALENZI FQ, MARLEY SB, CHANDRASHEKRAN A, WARRENS AN, GOLDMAN JM, GORDON MY: A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics. Exp. Hematol (2002) 30:1428–1435.
   PubMed Web of Science ®Google Scholar
• ASHKENAZI A, DIXIT VM: Death receptors: signaling and modulation. Science (1998) 281:1305–1308.
   PubMed Web of Science ®Google Scholar
• ROTH W, WAGENKNECHT B, KLUMPP A et al: APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ. (2001) 8:403–410.
   PubMed Web of Science ®Google Scholar
• LEITHAUSER F, DHEIN J, MECHTERSHEIMER G et al.: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. (1993) 69:415–429.
   PubMed Web of Science ®Google Scholar
• SUDA T, TAKAHASHI T, GOLSTEIN P, NAGATA S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 75:1169–1178.
   PubMed Web of Science ®Google Scholar
• GREEN DR, FERGUSON TA: The role of Fas ligand in immune privilege. Nat. Rev Ma Cell. Biol. (2001) 2:917–924.
   PubMed Web of Science ®Google Scholar
• DAI CH, PRICE JO, BRUNNER T, KRANTZ SB: Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood(1998) 91:1235–1242.
   PubMed Web of Science ®Google Scholar
• NAGAFUJI K, SHIBUYA T, HARADA M et al: Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood(1995) 86:883–889.
   PubMed Web of Science ®Google Scholar
• ISMAIL M, GIBSON FM, GORDON SMITH EC, RUTHERFORD TR: Bc1-2 and Bcl-x expression in the CD34+ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen. Br. J. Haematol (2001) 113:706–712.
   PubMed Web of Science ®Google Scholar
• KILLICK SB, COX CV, MARSH JC, GORDON SMITH EC, GIBSON FM: Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br. Haematol (2000) 111:1164–1169.
   PubMed Web of Science ®Google Scholar
• GERSUK GM, LEE JW, BECKHAM CA, ANDERSON J, DEEG HJ: Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood (1996) 88:1122–1123.
   PubMed Web of Science ®Google Scholar
• OSORIO LM, AGUILAR SANTELISES M, DE SANTIAGO A, HACHIYA T, MELLSTEDT H, JONDAL M: Increased serum levels of soluble Fas in progressive B-CLL. Eur. Haematol (2001) 66:342–346.
   PubMed Web of Science ®Google Scholar
• LANDOWSKI TH, MOSCINSKI L, BURKE R et al.: CD95 antigen mutations in hematopoietic malignancies. Leak. Lymphoma (2001) 42:835–846.
   PubMed Web of Science ®Google Scholar
• OWEN-SCHAUB L, CHAN H, CUSACK JC, ROTH J, HILL LL: Fas and Fas ligand interactions in malignant disease. Int.j amyl. (2000) 17:5–12.
   Web of Science ®Google Scholar
• GUO B, GODZIK A, REED JC: Bcl-G, anovel pro-apoptotic member of the Bc1-2 family. J. Biol Chem. (2001) 276:2780–2785.
   PubMed Web of Science ®Google Scholar
• KE N, GODZIK A, REED JC: Bcl-B, a novel Bc1-2 family member that differentially binds and regulates Bax and Bak. I. Biol. Chem. (2001) 276:12481–12484.
   Web of Science ®Google Scholar
• ODA E, OHKI R, MURASAWA H et al:Noxa, a BH3-only member of the Bc1-2 family and candidate mediator of p53-induced apoptosis. Science (2000) 288:1053–1058.
   PubMed Web of Science ®Google Scholar
• CLEARY ML, SMITH SD, SKLAR J: Cloning and structural analysis of cDNAs for bc1-2 and a hybrid bc1-2/ immunoglobulin transcript resulting from the t(14;18) translocation. Cell (1986) 47:19–28.
   PubMed Web of Science ®Google Scholar
• TSUJIMOTO Y, GORHAM J, COSSMAN J, JAFFE E, CROCE CM: The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science (1985) 229:1390–1393.
   PubMed Web of Science ®Google Scholar
• VAUX DL, CORY S, ADAMS JM: Bc1-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (1988) 335:440–442.
   PubMed Web of Science ®Google Scholar
• TSUJIMOTO Y: Stress-resistance conferred by high level of bc1-2 alpha protein in human B lymphoblastoid cell. Oncogene (1989) 4:1331–1336.
   PubMed Web of Science ®Google Scholar
• LAGASSE E, WEISSMAN IL: Bc1-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. Exp. Med. (1994) 179:1047–1052.
   PubMed Web of Science ®Google Scholar
• ZHONG LT, SARAFIAN T, KANE DJ et al: Bc1-2 inhibits death of central neural cells induced by multiple agents. Proc. Natl Acad. Sci. USA (1993) 90:4533–4537.
   PubMed Web of Science ®Google Scholar
• VANHAESEBROECK B, REED JC, DE VALCK D et al.: Effect of bc1-2 proto-oncogene expression on cellular sensitivity to tumor necrosis factor-mediated cytotoxicity. Oncogene (1993) 8:1075–1081.
   Google Scholar
• NUNEZ G, LONDON L, HOCKENBERY D, ALEXANDER M, MCKEARN JP, KORSMEYER SJ: Deregulated Bc1-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. Immunol. (1990) 144:3602–3610.
   Web of Science ®Google Scholar
• WANG Y, SZEKELY L, OKAN I, KLEIN G, WIMAN KG: Wild-type p53-triggered apoptosis is inhibited by bc1-2 in a v-myc-induced T-cell lymphoma line. Oncogene (1993) 8:3427–3431.
   PubMed Web of Science ®Google Scholar
• REED JC, KITADA S, TAKAYAMA S, MIYASHITA T: Regulation of chemoresistance by the bc1-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann. Oncol (1994) 5 (Suppl.) :161.
   Google Scholar
• TSUJIMOTO Y: Stress-resistance conferred by high level of bc1-2 alpha protein in human B lymphoblastoid cell. Oncogene (1989) 4:1331–1336.
   PubMed Web of Science ®Google Scholar
• SILVA M, RICHARD C, BENITO A, SANZ C, OLALLA I, FERNANDEZ-LUNA JL: Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl. I Med. (1998) 338:613–615.
   PubMedGoogle Scholar
• KORSMEYER SJ: Bc1-2 initiates a new category of oncogenes: regulators of cell death. Blood(1992) 80:879–886.
   PubMed Web of Science ®Google Scholar
• LOTEM J, SACHS L: Regulation by bc1-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ. (1993) 4:41–47.
   PubMedGoogle Scholar
• MIYASHITA T, REED JC: Bc1-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood (1993) 81:151–157.
   PubMed Web of Science ®Google Scholar
• LAURIA F, RASPADORI D et al: High bc1-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia (1997) 11:2075–2078.
   PubMed Web of Science ®Google Scholar
• PORWIT-MACDONALD A, IVORY K, WILKINSON S, WHEATLEY K, WONG L, JANOSSY G: Bc1-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia (1995) 9:1191–1198.
   PubMed Web of Science ®Google Scholar
• PALLIS M, ZHU YM, RUSSELL NH: Bc1-xL is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia (1997) 11:945–949.
   PubMed Web of Science ®Google Scholar
• KLASA RJ, GILLUM AM, KLEM RE, FRANKEL SR: Oblimmen Bc1-2 antisense:facilitating apoptosis in anticancer treatment. Antisense Nucleic Add Drug Dev. (2002) 12:193–213.
   PubMedGoogle Scholar
• WEBB A, CUNNINGHAM D, COTTER F et al: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349:1137–1141.
   PubMed Web of Science ®Google Scholar
• KEESHAN K, MILLS KI, COTTER TG, MCKENNA SL: Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug- resistant phenotype. Leukemia. (2001) 15:1823–1833.
   PubMed Web of Science ®Google Scholar
• HANDA H, HEGDE UP, KOTELNIKOV VM et al.: Bc1-2 and c-Myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase. Leak. Res. (1997) 21:479–489.
   PubMed Web of Science ®Google Scholar
• REED JC, CUDDY M, HALDAR S et al: Bc1-2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with Myc and inhibition by Bc1-2 antisense. Proc. Natl. Acad. ScL USA (1990) 87:3660-3664. N.FANG G, KIM CN, PERKINS CL et al.: CGP57148B (5TI571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood (2000) 96:2246–2253.
   Google Scholar
• HORITA M, ANDREU EJ, BENITO A et al.: Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bc1-xL. Exp. Med. (2000) 191:977–984.
   PubMed Web of Science ®Google Scholar
• KITADA S, ANDERSEN J, AKAR S et al: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with ha vitro and In vivo chemoresponses. Blood (1998) 91:3379–3389.
   PubMed Web of Science ®Google Scholar
• SCHEID S, HEINZINGER M, WALLER CE LANGE W: Bc1-2 mRNA-targeted ribozymes: effects on programmed cell death in chronic myelogenous leukemia cell lines. Ann. Hematol (1998) 76:117–125.
   PubMed Web of Science ®Google Scholar
• JIA L, MACEY MG, YIN Y, NEWLAND AC, KELSEY SM: Subcellular distribution and redistribution of Bc1-2 family proteins in human leukemia cells undergoing apoptosis. Blood (1999) 93:2353–2359.
   PubMed Web of Science ®Google Scholar
• HORITA M, ANDREU EJ, BENITO A et al.: Blockade of the BCR-ABL kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bc1-xL. Exp. Med. (2000) 191:977–984.
   PubMed Web of Science ®Google Scholar
• BELLAMY CO: p53 and apoptosis. Br. Med. Bull. (1997) 53:522–538.
   PubMed Web of Science ®Google Scholar
• LEVINE AJ, MOMAND J, FINLAY CA: The p53 tumour suppressor gene. Nature (1991) 351:453–456.
   PubMed Web of Science ®Google Scholar
• OREN M: p53: the ultimate tumor suppressor gene? FASEB J. (1992) 6:3169-3176.
   Google Scholar
• PROKOCIMER M, ROTTER V: Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood(1999) 484:2391–2411.
   Google Scholar
• AHUJA H, BAR ELI M, ARLIN Z et al:The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. Gin. Invest. (1991) 87:2042–2047.
   PubMed Web of Science ®Google Scholar
• EL-ROUBY S, THOMAS A, COSTIN D et al.: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood (1993) 82:3452–3459.
   PubMed Web of Science ®Google Scholar
• WATTEL E, PREUDHOMME C, HECQUET B et al.: p53 mutations are associated with resistance to chemotherapy and short survival in haematologic malignancies. Blood (1994) 84:3148–3157.
   PubMed Web of Science ®Google Scholar
• CORDONE I, MASI S, MAURO FR et al: p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood (1998) 91:4342–4349.
   PubMed Web of Science ®Google Scholar
• SANDER CA, YANO T, CLARK HM et al.: p53 mutation is associated with progression in follicular lymphomas. Blood (1993) 82: 1994-2004.
   Google Scholar
• NAKAI H, MISAWA S, TANAKA S et al.: p53 gene mutations and loss of a chromosome 17p in Philadelphia chromosome (Ph1)-positive acute leukemia. Leukemia (1993) 7:1547–1551.
   PubMed Web of Science ®Google Scholar
• FENAUX P, JONVEAUX P, QUIQUANDON I et al.: P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood (1991) 78: 1652-1657.
   Google Scholar
• EHINGER M, NILSSON E, PERSSON AM, OLSSON I, GULLBERG U: Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562. Cell Growth Differ. (1995) 6:9–17.
   PubMedGoogle Scholar
• LOTEM J, SACHS L: Hematopoietic cellsfrom mice deficient in wild type p53 are more resistant to induction of apoptosis by some agents. Blood (1993) 82:1092–1096.
   PubMed Web of Science ®Google Scholar
• LOWE SW, SCHMITT EM, SMITH SW, OSBORNE BA, JACKS T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 362:847–849.
   PubMed Web of Science ®Google Scholar
• CLARKE AR, PURDIE CA, HARRISON DJ et al.: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 362:849–852.
   PubMed Web of Science ®Google Scholar
• BI S, BARTON CM, LEMOINE NR, CROSS NC, GOLDMAN JM: Retroviral transduction of Philadelphia-positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation. Exp. Hematol (1994) 22:95–99.
   PubMed Web of Science ®Google Scholar
• LANZA F, BI S, MORETTI S, CASTOLDI G, GOLDMAN JM: Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides. Br. Haematol (1995) 90:8–14.
   PubMed Web of Science ®Google Scholar
• RAMQVIST T, MAGNUSSON KP, WANG Y, SZEKELY L, KLEIN G, WIMAN KG: Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene (1993) 8:1495–1500.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, DEISSEROTH A, KURZROCK R, ESTROV Z, TALPAZ M: Chronic myelogenous leukemia: a concise update. Blood (1993) 82:691–703.
   PubMed Web of Science ®Google Scholar
• MELO JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood (1996) 88:2375–2384.
   PubMed Web of Science ®Google Scholar
• DEININGER MW, GOLDMAN JM, MELO JV: The molecular biology of chronic myeloid leukemia. Blood (2000) 96:3343–3356.
   PubMed Web of Science ®Google Scholar
• •Recommended reading.
   Google Scholar
• GORDON MY, DOWDING CR, RILEY GP, GOLDMAN JM, GREAVES MF: Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature (1987) 328:342–344.
   PubMed Web of Science ®Google Scholar
• VERFAILLIE CM, MCCARTHY JB, MCGLAVE PB: Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. j Clin. Invert. (1992) 90:1232–1241.
   Google Scholar
• GORDON MY, DAZZI F, MARLEY SB et al.: Cell biology of CML cells. Leukemia (1999) 13(Suppl 1):S65–S71.
   PubMedGoogle Scholar
• GORDON MY, GOLDMAN JM: Cellularand molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br: J. Haematol. (1996) 95:10–20.
   PubMed Web of Science ®Google Scholar
• CHASTY RC, LUCAS GS, OWEN LYNCH PJ, PIERCE A, WHETTON AD: Macrophage inflammatory protein-1 alpha receptors are present on cells enriched for CD34 expression from patients with chronic myeloid leukemia. Blood (1995) 86:4270–4277.
   PubMed Web of Science ®Google Scholar
• CASHMAN JD, EAVES CJ, SARRIS AH, EAVES AC: MCP-1, not MIP-lalpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood(1998) 92:2338–2344.
   PubMed Web of Science ®Google Scholar
• AGLIETTA M, STACCHINI A, SEVERINO A, SANAVIO F, FERRANDO ML, PIACIBELLO W: Interaction of transforming growth factor-beta 1 with hemopoietic growth factors in the regulation of human normal and leukemic myelopoiesis. Exp. Hematol. (1989) 17:296–299.
   PubMed Web of Science ®Google Scholar
• HARIHARAN IK, ADAMS JM, CORY S: BCR-ABL oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res. (1988) 3:387–399.
   PubMedGoogle Scholar
• MANDANAS RA, BOSWELL HS, LU L, LEIBOWITZ D: BCR-ABL confers growth factor independence upon a murine myeloid cell line. Leukemia (1992) 6:796–800.
   PubMed Web of Science ®Google Scholar
• SIRARD C, LANEUVILLE P, DICK J: Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic MO7E cells by an autocrine mechanism. Blood(1994) 83:1575–1585.
   PubMed Web of Science ®Google Scholar
• CORTEZ D, KADLEC L, PENDERGAST AM: Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. MM. Cell. Biol. (1995) 15:5531–5541.
   Web of Science ®Google Scholar
• BEDI A, ZEHNBAUER BA, BARBER JP, SHARKIS SJ, JONES RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood (1994) 83:2038–2044.
   PubMed Web of Science ®Google Scholar
• DALEY GQ, BALTIMORE D: Transfection of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA (1988) 85:9312–9316.
   PubMed Web of Science ®Google Scholar
• OETZEL C, JONULEIT T, GOTZ A et al.: The tyrosine kinase inhibitor CGP57148 (5T1571) induces apoptosis in BCR-ABL-positive cells by down-regulating Bcl-X. Clin. Cancer Res. (2000) 6:1958–1968.
   PubMed Web of Science ®Google Scholar
• BEDI A, BARBER JP, BEDI GC et al: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood (1995) 86:1148–1158.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL: The role of myc in transformation by BCR-ABL. Leak. Lymphoma (1993) 11 (Suppl 1):45–46.
   PubMed Web of Science ®Google Scholar
• AMARANTE-MENDES GP, NAEKYUNG KIM C, LIU L et al.: BCR-ABL exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood (1998) 91: 1700-1705.
   Google Scholar
• AMOS TA, LEWIS JL, GRAND FH, GOODING RP, GOLDMAN JM, GORDON MY: Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br. Haematol. (1995) 91:387–393.
   PubMed Web of Science ®Google Scholar
• ALBRECHT T, SCHWAB R, HENKES M, PESCHEL C, HUBER C, AULITZKY WE: Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br. Haematol. (1996) 95:501–507.
   PubMed Web of Science ®Google Scholar
• SANTUCCI MA, ANKLESARIA P, LANEUVILLE P et al.: Expression of p210 BCR-ABL increases hematopoietic progenitor cell radiosensitivity. hat. Oncol. Biol. Phys. (1993) 26:831–836.
   PubMed Web of Science ®Google Scholar
• ROGER R, ISSAAD C, PALLARDY M et al.: BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood (1996) 87:1113–1122.
   PubMed Web of Science ®Google Scholar
• THIELE J, ZIRBES T, LORENZEN J et al.: Apoptosis and proliferation (PCNA labelling) in CML, a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy. Pathol. (1997) 181:316–322.
   Web of Science ®Google Scholar
• NICHOLSON DW: From bench to clinic with apoptosis-based therapeutic agents. Nature (2000) 407:810–816.
   PubMed Web of Science ®Google Scholar
• •Recommended reading.
   Google Scholar
• LOS M, HERR I, FRIESEN C, FULDA S, SCHULZE-OSTHOFF K, DEBATIN KM: Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood (1997) 90:3118–3129.
   PubMed Web of Science ®Google Scholar
• FAVROT M, COLL JL, LOUIS N, NEGOESCU A: Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Thec (1998) 5:728–739.
   PubMed Web of Science ®Google Scholar
• •Recommended reading.
   Google Scholar
• KERR RR, HARMON BV: Definition and incidence of apoptosis: an historical perspective. In: Current Communications in Cell and Molecular Biology Vol. 3, Tomei LD, Cope FO (Eds), Cold Spring Harbor Laboratory Press: Cold Spring Harbor (1991):5–29.
   Google Scholar
• REED JC, CUDDY M, HALDAR S et al.: BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc. Nati Acad. Sci. USA (1990) 87:3660–3664.
   PubMed Web of Science ®Google Scholar
• HOLLEMAN A, DEN BOER ML, KAZEMIER KM, JANKA-SCHAUB GE, PIETERS R: Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood(2003) 102:4541–4546.
   PubMed Web of Science ®Google Scholar
• WATERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of bc1-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. Clin. Oncol. (2000) 18:1812–1823.
   Web of Science ®Google Scholar
• LOTEM J, SACHS L: Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia (1996) 10:925–931.
   PubMed Web of Science ®Google Scholar
• WICKREMASINGHE RG, HOFFBRAND AV: Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood (1999) 93:3587–3600.
   PubMed Web of Science ®Google Scholar
• VERGILIO JA, BAGG A: Myelodysplastic syndromes. Contemporary biologic concepts and emerging diagnostic approaches. Am. Clin. Pathol (2003) 119(Suppl.):S58–S77.
   Google Scholar
• PARKER JE, MUFTI GJ: The myelodysplastic syndromes: a matter of life or death. Acta Haematol (2004) 111:78–99.
   PubMed Web of Science ®Google Scholar
• •Recommended reading.
   Google Scholar
• MUFTI G, LIST AF, GORE SD, HO AY: Myelodysplastic syndrome. Hematology (Am. Soc. Hematol Educ. Program) (2003):176–199.
   PubMedGoogle Scholar
• ERBA HP: Recent progress in the treatment of myelodysplastic syndrome in adult patients. Curc Opin. Omni (2003) 15:1–9.
   PubMed Web of Science ®Google Scholar
• TU C, ZHANG Y, LU H: Study of apoptosis by indomethacin in chronic myeloid leukaemia. Zhonghua Xue Ye Xue Za Zhi (1999) 20:362–365.
   PubMedGoogle Scholar
• GARTENHAUS RB, PRACHAND SN, PANIAQUA M, LI Y, GORDON LI: Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin. Cancer Res. (2002) 8:566–572.
   PubMed Web of Science ®Google Scholar
• MAHIEUX R, PISE-MASISON C, GESSAIN A et al.: Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bc1-2 cleavage. Blood (2001) 98:3762–3769.
   PubMed Web of Science ®Google Scholar
• LEER, WOLDA S, MOON E, ESSELSTYN J, HERTEL C, LERNER A: PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell. Signal. (2002) 14:277–284.
   PubMed Web of Science ®Google Scholar
• HAGISAWA S, MIKAMI T, SATO Y: Docetaxel-induced apoptosis in the mitotic phase: electron microscopic and cytochemical studies of human leukemia cells. Med. Dectron Microsc. (1999) 32:167–174.
   PubMedGoogle Scholar
• MOON E, LEE R, NEAR R, WEINTRAUB L, WOLDA S, LERNER A: Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Clin. Cancer Res. (2002) 8:589–595.
   PubMed Web of Science ®Google Scholar
• PLASILOVA M, ZIVNY J, JELINEK J et al: TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia. progenitors. Leukemia (2002) 16:67–73.
   PubMed Web of Science ®Google Scholar
• DIRSCH VM, ANTLSPERGER DS, HENTZE H, VOLLMAR AM: Ajoene, an experimental anti-leukemic drug: mechanism of cell death. Leukemia (2002) 16:74–83.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2:561–566.
   PubMed Web of Science ®Google Scholar
• BERNHARD D, SKVORTSOV S, TINHOFER I et Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ (2001) 8:1014–1021.
   PubMed Web of Science ®Google Scholar
• FOSTER BA, COFFEY HA, MORIN MJ, RASTINEJAD F: Pharmacological rescue of mutant p53 conformation and function. Science (1999) 286:2507–2510.
   PubMed Web of Science ®Google Scholar
• WEI SJ, CHAO Y, SHIH YL, YANG DM, HUNG YM, YANG WK: Involvement of Fas (CD95/AP0-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase. Gene Ther. (1999) 6:420–431.
   PubMed Web of Science ®Google Scholar
• SPIEKERMANN K, DIRSCHINGER RJ, SCHWAB R et al: The protein tyrosine kinase inhibitor 5U5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood (2002) 101:1494–1504.
   PubMed Web of Science ®Google Scholar
• LIU SY, PRESS OW: The potential for immunoconjugates in lymphoma therapy. Hematol Oncol Clin. North Am. (1997) 11:987–1006.
   PubMed Web of Science ®Google Scholar
• FRANKEL AE, LAVER JH, WILLINGHAM MC, BURNS LJ, KERSEY JH, VALLERA DA: Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotwdn. Leak. Lymphoma (1997) 26:287–298.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: Antibodies as cytotoxic therapy.j Clin. Oncol (1994) 12:1497–1515.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90:2188–2195.
   PubMed Web of Science ®Google Scholar
• BYRD JC, KITADA S, FLINN IW et al.: The mechanism of tumor cell clearance by rituximab in vivoin patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood (2002) 99:1038–1043.
   PubMed Web of Science ®Google Scholar
• PEDERSEN IM, BUHL AM, KLAUSEN P, GEISLER CH, JURLANDER J: The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood (2002) 99:1314–1319.
   PubMed Web of Science ®Google Scholar
• CHOW KU, SOMMERLAD WD, BOEHRER S et al.: Anti-CD 20antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes M vitro: role of cytokines, complement, and caspases. Haematologica (2002) 87:33–43.
   PubMed Web of Science ®Google Scholar
• GLENNIE MJ, HONEYCHURCH J, FRENCH RR, TUTT AL: The application of monoclonal antibodies in the treatment of lymphoma. In: Methods in Molecular Medicine Vol 40: Diagnostic and therapeutic antibodies, George AJT, Urch CE (Eds), Humana Press (1999):85.
   Google Scholar
• MA D, MCDEVITT MR, BARENDSWAARD E et al: Radio-immunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia (2002) 16:60–66.
   PubMed Web of Science ®Google Scholar
• LARSON RA, BOOGAERTS M, ESTEY E et al: Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia (2002) 16:1627–1636.
   PubMed Web of Science ®Google Scholar
• WAXMAN DJ, SCHWARTZ PS: Harnessing apoptosis for improved anticancer gene therapy. Cancer Res. (2003) 63:8563–8572.
   PubMed Web of Science ®Google Scholar
• VALLERA DA, JIN N, SHUY, PANOSKALTSIS-MORTARI A, KELEKAR A, CHEN W: Retroviral immunotwdn gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleulkin-3/Bax fusion protein gene. Hum. Gene Ther: (2003) 14:1787–1798.
   Google Scholar
• NAKAJIMA A, TAUCHIT, SASHIDA G et al.: Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia (2003) 17:560–567.
   PubMed Web of Science ®Google Scholar
• CIOCA DP, AOKI Y, KIYOSAWA K: RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther. (2003) 10:125–133.
   PubMed Web of Science ®Google Scholar
• O'DWYER ME, MAURO MJ, DRUKER BJ: 5TI571 as a targeted therapy for CML. Cancer Invest. (2003) 21:429–438.
   PubMed Web of Science ®Google Scholar
• O'DWYER ME, MAURO MJ, BLASDE C et al Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Bleed (2004) 103:451–455.
   PubMed Web of Science ®Google Scholar
• OTA J, YAMASHITA Y, OKAWA K et al: Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders. Oncegene (2003) 22:5720–5728.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-WOLF GD, SCHMIDT-WOLF IG: Gene therapy for hematological malignancies. Clin. Exp. Med. (2003) 3:4–14.
   PubMed Web of Science ®Google Scholar
• •Recommended reading.
   Google Scholar